Author:
Holt S,Bertelli G,Humphreys I,Valentine W,Durrani S,Pudney D,Rolles M,Moe M,Khawaja S,Sharaiha Y,Brinkworth E,Whelan S,Jones S,Bennett H,Phillips C J
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Aebi S, Davidson T, Gruber G, Castiglione M (2010) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v9–v14
2. Albain KS, Barlow WE, Shak S, Gabriel N, Hortobagyi GN, Livingston Robert B, Yeh I-Tien, Ravdin Peter, Bugarini Roberto, Baehner Frederick L, Davidson Nancy E, Sledge George W, Winer Eric P, Hudis Clifford, Ingle James N, Perez Edith A, Pritchard Kathleen I, Shepherd Lois, Gralow Julie R, Yoshizawa Carl, Craig Allred D, Kent Osborne C, Hayes Daniel F (2010) Prognostic and predictive value of the 21-gene recurrence score assay in a randomized trial of chemotherapy for postmenopausal, node-positive, estrogen receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11 (1): 55–65
3. Albanell J, Colomer R, Ruiz Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A (2012a) Prospective transGEICAM study of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol 23: 625–631
4. Albanell J, Gligorov J, Holt S, Blohmer J, Eiermann W, Svedmann C (2012b) Meta-Analysis of Prospective European Studies Assessing the Impact of Using the 21-gene Recurrence Score Assay on Clinical Decision Making in Women with ER+, HER2- Early Stage Breast Cancer. Poster 252PD, European Society of Medical Oncology: Vienna
5. Blohmer JU, Rezai M, Kümmel S (2012) Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ 16: 30–40